What do systematic reviews say?

Rituximab vs placebo

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Summary of findings for conjunctival autograft vs amniotic membrane transplant

The review found no eligible studies for this question.

• Conjunctival autograft for pterygium 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: bevacizumab vs ranibizumab

Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).

• Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
  RR 0.96 [0.9, 1.04]
  1 study · 548 participants
  Moderate

Rituximab vs intravenous methylprednisolone

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

Anti‐VEGF vs control

Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).

• Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
  MD 6.69 [3.38, 9.99]
  2 studies · 1134 participants
  Moderate

Summary of Findings Table ‐ Large retro‐equatorial recession of horizontal rectus muscle of 9 mm on the medial rectus and 12 mm on the lateral rectus vs simple tenotomy and resuturing of the 4 horizontal rectus muscles

• Surgical interventions for infantile nystagmus syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 10 participants
  Very low

Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham

• Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 983 participants
  High

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

The review found no eligible studies for this question.

• Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

The review found no eligible studies for this question.

• Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

• Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1003 participants
  Moderate